Pipeline Therapeutics to Present Preclinical Poster on PIPE-791 at the Glial Biology: Functional Interactions Among Glia Neurons, a Gordon Research Conference (GRC)

SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that it will present a poster highlighting the preclinical profile of PIPE-791 at the Glial Biology: Functional Interactions Among Glia and Neurons, a Gordon Research Conference (GRC), being held March 5-10, 2023, in Ventura, CA.

Poster Presentation Details:

Title: “PIPE-791 inhibits LPA1 to promote myelination and limit neuroinflammation”
Poster Session Date: March 8 and 9, 2023

The Glial Biology: Functional Interactions Among Glia and Neurons GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research.

More information can be found on the meeting website at 2023 Glial Biology: Functional Interactions Among Glia and Neurons Conference GRC.

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials - a SAD/MAD study and a PET study - in healthy volunteers, and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting MS patients.

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.